临床荟萃 ›› 2021, Vol. 36 ›› Issue (10): 937-941.doi: 10.3969/j.issn.1004-583X.2021.10.014

• 论著 • 上一篇    下一篇

症状性下肢动脉疾病抗栓治疗分析

陈隽1(), 周一薇1, 李秀娟2   

  1. 1.福建中医药大学附属第二人民医院 心内科,福建 福州 350001
    2.福建中医药大学附属第三人民医院 心内科, 福建 闽侯 350108
  • 收稿日期:2021-08-09 出版日期:2021-10-20 发布日期:2021-11-10
  • 通讯作者: 陈隽 E-mail:cjbb126@163.com
  • 基金资助:
    福建省卫生健康科技计划项目——健心颗粒在心力衰竭中通过mTOR信号通路调控自噬的作用机制研究(2020GGA068)

Analysis of antithrombotic therapy for symptomatic lower extremity atherosclerosis disease

Chen Jun1(), Zhou Yiwei1, Li Xiujuan2   

  1. 1. Department of Cardiology, the Second Affiliated People's Hospital of Fujian University of Traditional Chinese Medicine, Fuzhou 350001, China
    2. Department of Cardiology, the Third Affiliated People's Hospital People's Hospital of Fujian University of Traditional Chinese Medicine, Minhou 350108, China
  • Received:2021-08-09 Online:2021-10-20 Published:2021-11-10
  • Contact: Chen Jun E-mail:cjbb126@163.com

摘要:

目的 探讨小剂量利伐沙班联合抗血小板药对症状性下肢动脉疾病患者的治疗效果。结论 回顾性分析167例下肢动脉粥样硬化病变患者,分为观察组和对照组,观察组为利伐沙班(2.5 mg, 2次/d)联合抗血小板药物西洛他唑(100 mg, 2次/d),对照组单联抗血小板西洛他唑(100 mg, 2次/d)。2组治疗并随访18个月,观察主要肢体不良事件、主要心脑血管事件以及主要出血事件。结果 观察组主要心脑血管事件、肢体主要不良事件较对照组明显下降(P<0.05),主要出血事件在两组比较差异无统计学意义(P>0.05)。方法 小剂量利伐沙班联合抗血小板药物西洛他唑可明显减少症状性下肢动脉疾病的心脑血管和肢体主要不良事件,改善预后,且具有安全性。

关键词: 动脉粥样硬化, 下肢, 栓塞,胆固醇, 血小板聚集抑制剂

Abstract:

Objective To explore the curative effects of low-dose rivaroxaban combined with ant-platelet drugs for symptomatic lower extremity atherosclerosis disease(LEASD).Methods The data of 167 LEASD patients were retrospectively analyzed and divided into observation group and control group. Patients in observation group were treated with antithrombotic therapy using rivaroxaban (2.5 mg, bid) combined with anti-platelet drug namely cilostazol (100 mg, bid), and those in control group with the same dose of cilostazol alone (100 mg, bid). A 18-month follow-up was performed. The key observation was major adverse limb events(MALEs), major adverse cardiovascular events(MACEs) and adverse bleeding events(MBEs).Results MACEs and MALEs were significantly lower in observation group than in control group (P<0.05). No differences were statistically significant in MBEs between groups (P>0.05).Conclusion For LEASD patient, low-dose rivaroxaban combined with anti-platelet drug namely cilostazol can significantly reduce MACEs and MALEs, and improve prognosis with safety.

Key words: atherosclerosis, lower extremity, embolism,cholesterol, platelet aggregation inhibitors

中图分类号: